FDA could approve MDMA to treat PTSD

The Food and Drug Administration is expected to decide in early August whether MDMA should be approved for treating post-traumatic stress disorder. The decision has garnered a huge amount of attention and lobbying by people who want the treatment to get the green light.

If approved, MDMA would represent a milestone in the efforts to bring psychedelics into the mainstream. However, the drug company behind the treatment has been mired in controversy, fending off criticism that the clinical trials weren’t sound. That has raised the possibility that the FDA reject the drug.

NPR’s Will Stone reports.

This article was originally published on WBUR.org.